Switching basal insulins in type 2 diabetes: practical recommendations for health care providers (Q48088343)

8 February 2018

http://europepmc.org/abstract/MED/29260929

review article

1 reference

title

Switching basal insulins in type 2 diabetes: practical recommendations for health care providers (English)

1 reference

8 February 2018

http://europepmc.org/abstract/MED/29260929

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

Jennifer M Trujillo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

Robert Tanenberg

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

author name string

John E Anderson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

20 December 2017

1 reference

8 February 2018

http://europepmc.org/abstract/MED/29260929

published in

Postgraduate Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

volume

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

229-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

The past, present, and future of basal insulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

The High Cost of Prescription Drugs in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Inpatient hyperglycemia management: A practical review for primary medical and surgical teams

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Clinical use of insulin degludec.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Patient Perspectives on Biosimilar Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Economic costs of diabetes in the U.S. in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2018.1419048

10.1080/00325481.2018.1419048

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29260929 AND SRC:MED&resulttype=core&format=json

31 May 2020

1 reference